- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05099003
En studie av läkemedlet Selinexor med strålbehandling hos patienter med nyligen diagnostiserat diffust Intrinsic Pontine (DIPG) gliom och höggradigt gliom (HGG)
En fas 1/2-studie av Selinexor (KPT-330) och strålbehandling vid nydiagnostiserade pediatriska diffusa intrinsiska pontinska gliom (DIPG) och höggradigt gliom (HGG)
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of selinexor administered as an oral formulation in combination with standard of care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). (Dose-finding phase/phase I) II. To estimate the event-free survival (EFS) distribution for diffuse midline glioma (DMG)/HGG patients and overall survival (OS) distribution for DIPG patients associated with selinexor plus RT, followed by selinexor in patients with newly diagnosed HGG (H3 K27M mutant DMG or H3 K27-wild type HGG) or DIPG, and to compare those outcomes to historical controls. (Efficacy phase/phase II)
EXPLORATORY OBJECTIVE:
I. To bank tumor specimens and body fluids (blood and cerebrospinal fluid) for future studies.
OUTLINE: This is a phase I dose-escalation study of selinexor followed by a phase II study. (STRATUM DIPG AND STRATUM DMG CLOSED TO ACCRUAL 02/14/2025)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor orally (PO) on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a magnetic resonance imaging (MRI) and may undergo a biopsy during screening.
MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up.
After completion of study treatment, patients are followed every 3 months for year 1 (i.e., 3, 6, 9, 12 months), then every 6 months for years 2-3 (i.e., 18, 24, 30, 36 months), and finally once yearly for years 4-5 of this study.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australien, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Queensland Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Perth Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- Children's Hospital of Alabama
-
-
Arizona
-
Mesa, Arizona, Förenta staterna, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Förenta staterna, 85016
- Phoenix Childrens Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Loma Linda, California, Förenta staterna, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Förenta staterna, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Förenta staterna, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Förenta staterna, 90027
- Children's Hospital Los Angeles
-
Madera, California, Förenta staterna, 93636
- Valley Children's Hospital
-
Oakland, California, Förenta staterna, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Förenta staterna, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Förenta staterna, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Förenta staterna, 94304
- Lucile Packard Children's Hospital Stanford University
-
San Diego, California, Förenta staterna, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Förenta staterna, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Förenta staterna, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33908
- Golisano Children's Hospital of Southwest Florida
-
Jacksonville, Florida, Förenta staterna, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Förenta staterna, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Förenta staterna, 33176
- Miami Cancer Institute
-
Orlando, Florida, Förenta staterna, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Förenta staterna, 32806
- Arnold Palmer Hospital for Children
-
St. Petersburg, Florida, Förenta staterna, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Förenta staterna, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60637
- University of Chicago Comprehensive Cancer Center
-
Peoria, Illinois, Förenta staterna, 61637
- OSF Children's Hospital of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Riley Hospital for Children
-
-
Iowa
-
Des Moines, Iowa, Förenta staterna, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Förenta staterna, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Förenta staterna, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Förenta staterna, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Förenta staterna, 48201
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Förenta staterna, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Förenta staterna, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Förenta staterna, 68114
- Children's Hospital and Medical Center of Omaha
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Förenta staterna, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Förenta staterna, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Förenta staterna, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Albany Medical Center
-
Buffalo, New York, Förenta staterna, 14263
- Roswell Park Cancer Institute
-
New Hyde Park, New York, Förenta staterna, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Förenta staterna, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Förenta staterna, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Förenta staterna, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Syracuse, New York, Förenta staterna, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Förenta staterna, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Charlotte, North Carolina, Förenta staterna, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Förenta staterna, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Förenta staterna, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Förenta staterna, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Förenta staterna, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Förenta staterna, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Oregon Health and Science University
-
Portland, Oregon, Förenta staterna, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, Förenta staterna, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Förenta staterna, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Förenta staterna, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Förenta staterna, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Förenta staterna, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Förenta staterna, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Förenta staterna, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Förenta staterna, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Förenta staterna, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Förenta staterna, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Förenta staterna, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Förenta staterna, 76104
- Cook Children's Medical Center
-
Houston, Texas, Förenta staterna, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Förenta staterna, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
San Antonio, Texas, Förenta staterna, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Förenta staterna, 78207
- Children's Hospital of San Antonio
-
Temple, Texas, Förenta staterna, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- University of Virginia Cancer Center
-
Norfolk, Virginia, Förenta staterna, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Förenta staterna, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Förenta staterna, 98405
- Mary Bridge Children's Hospital and Health Center
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Québec, Kanada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Kanada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Christchurch, Nya Zeeland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Nya Zeeland, 1145
- Starship Children's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
PRE ENROLLMENT: Patients must be =< 25 years of age at the time of enrollment on APEC14B1 part A central nervous system (CNS)/high grade glioma (HGG) pre-enrollment eligibility screening
-
Please note:
- This required age range applies to pre-enrollment eligibility for all HGG patients. Individual treatment protocols may have different age criteria.
- Non-DIPG patients with tumors that do not harbor an H3K27M-mutation and are >= 18 years of age will not be eligible to enroll on ACNS1821 (Step 1).
-
-
PRE ENROLLMENT: Patient is suspected of having localized, newly diagnosed HGG, excluding metastatic disease, OR patient has an institutional diagnosis of DIPG
- Please note: there are specific radiographic criteria for DIPG patient enrollment on ACNS1821 (Step 1)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors: Patients and/or their parents or legal guardians must have signed informed consent for eligibility screening on APEC14B1 Part A.
- For patients with DIPG: Patients and/or their parents or legal guardians must have signed informed consent for ACNS1821.
- Note: As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors only, the specimens obtained at the time of diagnostic biopsy or surgery must be submitted through APEC14B1 ASAP, preferably within 5 calendar days of definitive surgery
-
STEP 1: Patients must be >= 12 months and =< 21 years of age at the time of enrollment
-
STEP 1: Patients must have newly-diagnosed DIPG or HGG (including DMG).
-
STEP 1: Stratum DIPG (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients with newly-diagnosed typical DIPG, defined as tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons on at least 1 axial T2 weighted image, are eligible. No histologic confirmation is required.
- Patients with pontine tumors that do not meet radiographic criteria for typical DIPG (e.g., focal tumors or those involving less than 2/3 of the pontine cross-sectional area with or without extrapontine extension) are eligible if the tumors are biopsied and proven to be high-grade gliomas (such as anaplastic astrocytoma, glioblastoma, high-grade glioma not otherwise specified [NOS], and/or H3 K27M-mutant) by institutional diagnosis.
-
STEP 1: Stratum DMG (with H3 K27M mutation) (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients must have newly-diagnosed non-pontine H3 K27M-mutant HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
- Note: Patients need not have either measurable or evaluable disease, i.e., DMG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment. For rare H3 K27M-mutant HGG in non-midline structures (e.g., cerebral hemispheres), these patients will be considered part of Stratum DMG.
-
STEP 1: Stratum HGG (without H3 K27M mutation)
-
Patients must have newly-diagnosed non-pontine H3 K27M-wild type HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
-
Please note:
- Patients who fall in this category and who are >= 18 years of age are not eligible due to another standard-of-care regimen (radiation/temozolomide) that is available
- Patients need not have either measurable or evaluable disease, i.e., HGG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment
-
-
STEP 1: Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =<16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
STEP 1: Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to step 1 enrollment)
-
STEP 1: Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to step 1 enrollment)
-
STEP 1: Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to step 1 enrollment)
-
STEP 1: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to step 1 enrollment) or
A serum creatinine based on age/sex as follows (within 7 days prior to step 1 enrollment):
-
Age / Maximum Serum Creatinine (mg/dL)
-
1 to < 2 years / male: 0.6; female: 0.6
-
2 to < 6 years / male: 0.8; female: 0.8
-
6 to < 10 years / male: 1; female: 1
-
10 to < 13 years / male: 1.2; female: 1.2
-
13 to < 16 years / male: 1.5; female: 1.4
-
>= 16 years / male: 1.7; female: 1.4
- STEP 1: Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
- STEP 1: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.
- STEP 1: Serum amylase =< 1.5 x ULN
- STEP 1: Serum lipase =< 1.5 x ULN
- STEP 1: No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination.
- STEP 1: Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
- STEP 1: Patients must be enrolled and protocol therapy must begin no later than 31 days after the date of radiographic diagnosis (in the case of non-biopsied DIPG patients only) or definitive surgery, whichever is the later date (Day 0).
-
For patients who have a biopsy followed by resection, the date of resection will be considered the date of definitive diagnostic surgery. If a biopsy only was performed, the biopsy date will be considered the date of definitive diagnostic surgery.
Exclusion Criteria:
-
STEP 1: Patients must not have received any prior therapy for their central nervous system (CNS) malignancy except for surgery and steroid medications.
-
STEP 1: Patients who are currently receiving another investigational drug are not eligible.
-
STEP 1: Patients who are currently receiving other anti-cancer agents are not eligible.
-
STEP 1: Patients >=18 years of age who have H3 K27M-wild type HGG.
-
STEP 1: Patients who have an uncontrolled infection.
-
STEP 1: Patients who have received a prior solid organ transplantation.
-
STEP 1: Patients with grade > 1 extrapyramidal movement disorder.
-
STEP 1: Patients with known macular degeneration, uncontrolled glaucoma, or cataracts.
-
STEP 1: Patients with metastatic disease are not eligible; MRI of spine with and without contrast must be performed if metastatic disease is suspected by the treating physician.
-
STEP 1: Patients with gliomatosis cerebri type 1 or 2 are not eligible, with the exception of H3 K27M-mutant bithalamic tumors.
-
STEP 1: Patients who are not able to receive protocol specified radiation therapy.
-
STEP 1:
- Female patients who are pregnant are ineligible since there is yet no available information regarding human fetal or teratogenic toxicities.
- Lactating females are not eligible unless they have agreed not to breastfeed their infants. It is not known whether selinexor is excreted in human milk.
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
- Sexually active patients of reproductive potential are not eligible unless they have agreed to use two effective methods of birth control (including a medically accepted barrier method of contraception, e.g., male or female condom) for the duration of their study participation and for 90 days after the last dose of selinexor. Abstinence is an acceptable method of birth control.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment (selinexor and radiation therapy)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a MRI and may undergo a biopsy during screening. MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up. |
Undergo radiation therapy
Andra namn:
Undergo a MRI
Andra namn:
Undergo a biopsy
Andra namn:
Given orally
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximum tolerated dose
Tidsram: From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
Defined as the highest dose of selinexor in combination with standard of care radiation therapy that does not cause unacceptable side effects. |
From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
|
Event free survival (EFS)
Tidsram: From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse midline glioma/ high grade glioma patients. EFS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
|
Overall Survival (OS)
Tidsram: From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse intrinsic pontine glioma patients. The OS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
|
Overall response rate
Tidsram: Up to 5 years
|
Defined as the proportion of patients whose best response is partial response or complete response. |
Up to 5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Adam L Green, Children's Oncology Group
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Neoplasmer, neuroepitelial
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Gliom
- Undersökningstekniker
- Terapeutik
- Provhantering
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Kirurgiska ingrepp, operativ
- Cytologiska tekniker
- Cytodiagnos
- Fysiska fenomen
- Diagnostiska tekniker, kirurgiska
- Kemitekniker, analytiska
- Spektrumanalys
- Strålbehandling
- Strålning
- Biopsi
- Magnetresonansspektroskopi
- selinexor
Andra studie-ID-nummer
- NCI-2021-11337
- U10CA180886 (U.S.S. NIH-anslag/kontrakt)
- NCI-2021-11337 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- ACNS1821 (Annan identifierare: CTEP)
- ACNS1821 (Annan identifierare: Children's Oncology Group)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .